First Light Asset Management LLC Purchases New Shares in Abivax SA Sponsored ADR $ABVX

First Light Asset Management LLC purchased a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 95,955 shares of the company’s stock, valued at approximately $8,147,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. UBS Group AG increased its position in Abivax by 2,561.0% in the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after acquiring an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Abivax during the third quarter worth approximately $263,698,000. Baker BROS. Advisors LP acquired a new position in shares of Abivax during the third quarter worth approximately $74,355,000. Jefferies Financial Group Inc. bought a new stake in shares of Abivax during the third quarter valued at approximately $38,827,000. Finally, Orbimed Advisors LLC bought a new stake in shares of Abivax during the third quarter valued at approximately $32,262,000. Institutional investors own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Truist Financial set a $140.00 price objective on shares of Abivax in a research report on Monday, November 24th. Oppenheimer set a $131.00 price objective on Abivax in a research report on Thursday, January 8th. Wall Street Zen cut Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Guggenheim reaffirmed a “buy” rating and set a $175.00 price target on shares of Abivax in a research note on Thursday, December 18th. Finally, Citigroup reiterated a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Abivax presently has a consensus rating of “Moderate Buy” and an average price target of $134.75.

Abivax Price Performance

Shares of ABVX stock opened at $115.50 on Monday. The firm’s 50 day moving average price is $118.99 and its two-hundred day moving average price is $109.10. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. Abivax SA Sponsored ADR has a 52-week low of $4.77 and a 52-week high of $148.83. The stock has a market cap of $9.13 billion, a PE ratio of -27.63 and a beta of 1.01.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The business had revenue of ($4.92) million for the quarter. As a group, analysts forecast that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.